title: Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
abstract: Unrelated donor marrow transplantation is associated with an increased incidence of graft-versus-host disease (GVHD) compared with sibling donor transplants. Forty-one patients undergoing unrelated donor transplants were treated with a GVHD prophylaxis regimen that consisted of continuous infusion cyclosporine from day -1 to 100 days post transplant along with nifedipine, glucocorticoids and short-course methotrexate. The regimen was well-tolerated in this cohort with mostly high risk disease. Fifty-one percent of patients developed acute GVHD, which was grade III-IV in 22% of patients. Six of 22 patients at risk for chronic GVHD developed extensive chronic GVHD, five of whom were adults. In patients <18 years of age, there was a >40% chance of 2 year disease-free survival. Use of continuous infusion cyclosporine with nifedipine as an immunosuppressant and protectant against cyclosporine-induced toxicities in unrelated donor transplants is well-tolerated, and results in acute GVHD incidence favorable to that reported with bolus cyclosporine.
authors.affiliation: Department of Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA.
authors.forename: J
authors.initials: J
authors.lastname: Liesveld
authors.forename: R
authors.initials: R
authors.lastname: Duerst
authors.forename: A
authors.initials: A
authors.lastname: Rapoport
authors.forename: L
authors.initials: L
authors.lastname: Constine
authors.forename: C
authors.initials: C
authors.lastname: Abboud
authors.forename: C
authors.initials: C
authors.lastname: Packman
authors.forename: L
authors.initials: L
authors.lastname: Wedow
authors.forename: L
authors.initials: L
authors.lastname: Zwetsch
authors.forename: B
authors.initials: B
authors.lastname: McKenna
authors.forename: T
authors.initials: T
authors.lastname: Linder
authors.forename: W
authors.initials: W
authors.lastname: Silverman
authors.forename: S
authors.initials: S
authors.lastname: Swift
authors.forename: J
authors.initials: J
authors.lastname: Rowe
authors.forename: J
authors.initials: J
authors.lastname: DiPersio
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000401:mortality; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D002423:Cause of Death; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007223:Infant; D015993:Life Tables; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage*; D016019:Survival Analysis; D014184:Transplantation, Homologous / Q000009:adverse effects* / Q000401:mortality; D016896:Treatment Outcome; D014923:Wiskott-Aldrich Syndrome / Q000628:therapy
chemical_list: D002121:Calcium Channel Blockers; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009543:Nifedipine; D008775:Methylprednisolone; D008727:Methotrexate